Literature DB >> 19009549

Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy.

Mohamed A Shaker1, Husam M Younes.   

Abstract

Despite the fact that different administration routes and delivery systems have been used for interleukin-2 (IL-2) delivery, little has been reported regarding the most efficient strategies used to deliver IL-2 in a nontoxic, efficient, stable and safe manner. Systemic IL-2 administration has always been associated with rapid clearance and severe toxicity as a result of its narrow therapeutic index. Loco-regional IL-2 delivery, however, is used to localize IL-2 actions and activities into the vicinity of tumors and can result in an improved therapeutic outcome with much less side effects or toxicity. The purpose of this review is to report on the different properties and aspects of IL-2, including its mechanism of action, physicochemical properties, and structure which have an impact on the activity, stability and formulation of IL-2 dosage forms and delivery systems. In addition, advantages and limitations of the currently available techniques and strategies to deliver IL-2 will also be covered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19009549     DOI: 10.1002/jps.21596

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

1.  In vitro assessment of choline dihydrogen phosphate (CDHP) as a vehicle for recombinant human interleukin-2 (rhIL-2).

Authors:  David M Foureau; Regina M Vrikkis; Chase P Jones; Katherine D Weaver; Douglas R Macfarlane; Jonathan C Salo; Iain H McKillop; Gloria D Elliott
Journal:  Cell Mol Bioeng       Date:  2012-12-01       Impact factor: 2.321

Review 2.  Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.

Authors:  Denise Skrombolas; John G Frelinger
Journal:  Expert Rev Clin Immunol       Date:  2014-02       Impact factor: 4.473

3.  A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Alexander Fefer; Brenda M Sandmaier; Theodore A Gooley; Edus H Warren; Stephen H Petersdorf; Jean E Sanders; Rainer F Storb; Frederick R Appelbaum; Paul J Martin; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

4.  Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.

Authors:  Nobuaki Kobayashi; Choongman Hong; Dennis M Klinman; Hidekazu Shirota
Journal:  J Immunol       Date:  2013-01-07       Impact factor: 5.422

Review 5.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

6.  Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity.

Authors:  Sharon H Chou; Aditya V Shetty; Yajun Geng; Lipeng Xu; Gnanasekar Munirathinam; Anne Pipathsouk; Isaiah Tan; Timothy Morris; Bin Wang; Aoshuang Chen; Guoxing Zheng
Journal:  Cancer Immunol Immunother       Date:  2012-11-04       Impact factor: 6.968

Review 7.  Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Cancer J       Date:  2021 Sep-Oct 01       Impact factor: 3.360

Review 8.  Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.

Authors:  Mariana Aris; María Marcela Barrio
Journal:  Front Immunol       Date:  2015-02-09       Impact factor: 7.561

9.  The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study.

Authors:  Annika N Haagsman; Astrid C S Witkamp; Bart E Sjollema; Marja J L Kik; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2013-08-08       Impact factor: 2.741

10.  Functional Modulation of Regulatory T Cells by IL-2.

Authors:  Byung-In Moon; Tae Hun Kim; Ju-Young Seoh
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.